Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05587361 · ClinicalTrials.gov registry record · Phase 4
Beta-Adrenergic Modulation of Drug Cue Reactivity
A Phase 4 study of Tobacco Use Disorder and Nicotine Dependence, sponsored by University of Oklahoma.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05587361: Recruiting Phase 4 study of Tobacco Use Disorder and Nicotine Dependence, sponsored by University of Oklahoma.
NCT05587361 is a Phase 4 study of Tobacco Use Disorder and Nicotine Dependence that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 80 participants, below the 238-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05587361, a Phase 4 study of Tobacco Use Disorder and Nicotine Dependence, is actively recruiting participants, sponsored by University of Oklahoma.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.
Primary Outcome
Self-reported smoking urges in response to smoking and non-smoking cues during magnetic resonance imaging (MRI) scan. Scores range from 0 to 10 with higher values indicating increased craving for cigarettes.
Conditions Studied
Interventions
- DRUG Propranolol
- DRUG Nicotine Patch
- DRUG Placebo Propranolol
- DRUG Placebo Patch
Study Locations (1)
Oklahoma
- Hardesty Center for Clinical Research and Neuroscience - Tulsa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-11-26 |
| Est. Completion | 2026-03-01 |
| Phase | Phase 4 |
What NCT05587361 shows while recruiting
NCT05587361 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 238-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (66% lower).
The record links to 3 conditions, with Tobacco Use Disorder appearing as the primary indexed condition, and to 4 interventions - of which Propranolol is the first listed.
NCT05587361 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT05587361 about?
NCT05587361 is a clinical study titled "Beta-Adrenergic Modulation of Drug Cue Reactivity". This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in h...
What is the current status of trial NCT05587361?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2024-11-26. Estimated completion is 2026-03-01.
What conditions does trial NCT05587361 study?
This clinical trial studies the following conditions: Tobacco Use Disorder, Nicotine Dependence, Cigarette Smoking.
What interventions are being tested in trial NCT05587361?
The interventions under investigation include: Propranolol (DRUG), Nicotine Patch (DRUG), Placebo Propranolol (DRUG), Placebo Patch (DRUG).
Who is sponsoring clinical trial NCT05587361?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05587361 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tobacco Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05587361's enrollment target sits among peer trials
80 43rd of 70 higher than 28 of 70 other Tobacco Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Tobacco Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
E-cigarette Cessation in Adults Who Co-use Cannabis
RECRUITING · Phase 4
-
Varenicline and Combined NRT for Smoking Cessation
ACTIVE NOT RECRUITING · Phase 4
-
Smokers' Health Project: Self-Determination and Maintaining Tobacco Abstinence
COMPLETED · Phase 4
-
A Comparison of Bupropion SR and Placebo for Smoking Cessation
COMPLETED · Phase 4
-
Varenicline Effects In Schizophrenic Smokers
COMPLETED · Phase 4
-
Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI